Biomerica Inc (NASDAQ:BMRA)
| Market Cap | $4.97M-51.6% |
| Revenue (ttm) | $4.34M-11.2% |
| Net Income | -$5.01M-37.0% |
| EPS | -$1.63-481.3% |
| Shares Out | 4.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,382 |
| Open | $1.08 |
| Previous Close | $1.10 |
| Day's Range | $1.06 - $1.10 |
| 52-Week Range | $1.01 - $2.94 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Jan 8, 2027 |
About BMRA
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Biomerica Inc Stock Analysis — InsiderScore
Biomerica Inc scored higher than 61% of companies evaluated by InsiderBuying, and ranked 20th out of 47 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Biomerica Inc bought $158.0K of stock across 5 purchases in the last 90 days, the largest of them $50.0K.
The average purchase added about 39% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Jan 8, 2027Earnings report
$BMRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BMRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BMRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BMRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BMRA Revenue by Segment or Geography
As of: Q3 2026 (Aug 31, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BMRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BMRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BMRA
| VXFVanguard Extended Market ETF | $24.82K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BMRA’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-17.0 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
